Androgen deprivation therapy (ADT) has long been a foundation in the management of prostate cancer. Since the introduction of ...

The global companion diagnostics market is set to surge from USD 7.03 Billion in 2024 to USD 22.83 Billion by 2034, driven by rising cancer prevalenc ...

The Cancer Immunotherapy market, valued at USD 220.94 billion in 2024, is expected to register robust revenue CAGR of 13.6%.

Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

SNY's SAR446597, a one-time intravitreal gene therapy, secures FDA fast track tag for geographic atrophy due to age-related ...

For the third time in four years, CNBC ranks North Carolina as Top State for Business. To learn more, click here. Hosted by the Central Carolina Community College's (CCCC) Biotechnology Department, ...

The global Oligonucleotide Synthesis Market is valued at USD 7.78 Billion in 2024 and is projected to reach a value of USD 21 ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will present 16 abstracts featuring new data across its approved cancer therapies at the 2025 American Society of ...

Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth, discusses strategies for managing costs of novel cellular and gene therapies in the oncology pipeline.

NEW YORK — To gene therapy pioneer Jim Wilson, the field is currently clouded with “irrational pessimism.” Companies are abandoning ship; approved therapies aren’t being prescribed.